JP5615902B2 - イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 - Google Patents

イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 Download PDF

Info

Publication number
JP5615902B2
JP5615902B2 JP2012502778A JP2012502778A JP5615902B2 JP 5615902 B2 JP5615902 B2 JP 5615902B2 JP 2012502778 A JP2012502778 A JP 2012502778A JP 2012502778 A JP2012502778 A JP 2012502778A JP 5615902 B2 JP5615902 B2 JP 5615902B2
Authority
JP
Japan
Prior art keywords
imidazo
thiadiazol
substituted
optionally
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012502778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522759A (ja
JP2012522759A5 (enExample
Inventor
フェルナンデス， ホアキン パストル
フェルナンデス， ホアキン パストル
ギド クルス，
ギド クルス，
ゴンサレス， ソニア マルティネス
ゴンサレス， ソニア マルティネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spanish National Cancer Research Centre
Original Assignee
Spanish National Cancer Research Centre
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spanish National Cancer Research Centre filed Critical Spanish National Cancer Research Centre
Publication of JP2012522759A publication Critical patent/JP2012522759A/ja
Publication of JP2012522759A5 publication Critical patent/JP2012522759A5/ja
Application granted granted Critical
Publication of JP5615902B2 publication Critical patent/JP5615902B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
JP2012502778A 2009-04-02 2010-04-01 イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体 Expired - Fee Related JP5615902B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09380069.6 2009-04-02
EP09380069 2009-04-02
PCT/GB2010/000674 WO2010112874A1 (en) 2009-04-02 2010-04-01 Imidazo [2, 1-b] [ 1, 3, 4 ] thiadiazole derivatives

Publications (3)

Publication Number Publication Date
JP2012522759A JP2012522759A (ja) 2012-09-27
JP2012522759A5 JP2012522759A5 (enExample) 2013-05-16
JP5615902B2 true JP5615902B2 (ja) 2014-10-29

Family

ID=40750794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012502778A Expired - Fee Related JP5615902B2 (ja) 2009-04-02 2010-04-01 イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体

Country Status (23)

Country Link
US (1) US8815918B2 (enExample)
EP (1) EP2414369B1 (enExample)
JP (1) JP5615902B2 (enExample)
KR (1) KR101727264B1 (enExample)
CN (1) CN102388055B (enExample)
AU (1) AU2010231162B2 (enExample)
BR (1) BRPI1015367B8 (enExample)
CA (1) CA2756873C (enExample)
CY (1) CY1116880T1 (enExample)
DK (1) DK2414369T3 (enExample)
EA (1) EA022753B1 (enExample)
ES (1) ES2548571T3 (enExample)
HR (1) HRP20151126T1 (enExample)
HU (1) HUE027964T2 (enExample)
IL (1) IL215158A (enExample)
MX (1) MX2011010372A (enExample)
NZ (1) NZ595674A (enExample)
PL (1) PL2414369T3 (enExample)
PT (1) PT2414369E (enExample)
SG (1) SG175001A1 (enExample)
SI (1) SI2414369T1 (enExample)
WO (1) WO2010112874A1 (enExample)
ZA (1) ZA201107350B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
GB2480815A (en) * 2010-06-01 2011-12-07 Summit Corp Plc Compounds for the treatment of clostridium difficile-associated disease
CA2801274C (en) 2010-06-01 2021-06-15 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
WO2012020217A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
WO2012020215A1 (en) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors
KR101594002B1 (ko) 2010-10-06 2016-02-15 글락소스미스클라인 엘엘씨 Ｐｉ３ 키나제 억제제로서의 벤즈이미다졸 유도체
TWI617559B (zh) 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
AU2012257513B2 (en) 2011-05-19 2017-05-11 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Macrocyclic compounds as protein kinase inhibitors
KR101399484B1 (ko) 2011-07-14 2014-05-29 한국화학연구원 허피스바이러스 엑소뉴클리에이즈 활성 억제 물질을 유효성분으로 함유하는 항허피스바이러스용 약학적 조성물
SG11201701580XA (en) 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
HRP20211778T1 (hr) 2014-08-29 2022-03-18 Chdi Foundation, Inc. Kontrastna sredstva za slikovnu dijagnostiku huntingtin proteina
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
MX2022004665A (es) 2019-10-21 2022-05-25 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias.
WO2022053838A1 (en) * 2020-09-14 2022-03-17 The University Of Sussex Small molecule inhibitors of lemur tyrosine kinase 3

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464259A (en) 1975-10-03 1977-02-09 Pfizer Ltd Imidazo-thiazole and -thiadiazole sulphonamides and their use as therapeutic agents
NO811630L (no) 1980-05-29 1981-11-30 Bayer Ag Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel
DE3208437A1 (de) 1982-03-09 1983-09-15 Bayer Ag, 5090 Leverkusen Imidazothiadiazolalkencarbonsaeureamide, neue zwischenprodukte zu ihrer herstellung, ihre herstellung und ihre verwendung in arzneimitteln
IT1269176B (it) 1994-01-11 1997-03-21 Isagro Srl Eterobicicli ad attivita' fungicida
AU7001396A (en) 1995-09-22 1997-04-09 Takeda Chemical Industries Ltd. Triazole compounds, their production and use
BR0113139A (pt) 2000-08-09 2003-06-24 Agouron Pharma Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase
CA2364985A1 (en) * 2001-12-14 2003-06-14 John W. Gillard Imidazo(2,1-b)thiadiazole sulfonamides
AU2003297161B8 (en) 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2527903A1 (en) * 2003-06-13 2004-12-23 Aegera Therapeutics, Inc. Imidazo[2,1-b]-1,3,4-thiadiazole sulfoxides and sulfones
CN1835956A (zh) 2003-06-13 2006-09-20 艾吉拉医疗股份有限公司 酰化和非酰化的咪唑并[2,1－b]－1,3,4,－噻二唑－2－磺酰胺及其用途
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US8178533B2 (en) 2005-06-01 2012-05-15 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7750000B2 (en) 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US7728017B2 (en) 2005-11-30 2010-06-01 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
US20090170845A1 (en) 2006-04-13 2009-07-02 Aegera Therapeutics Inc. USE OF IMIDAZO[2,1-b]-1,3,4-THIADIAZOLE-2-SULFONAMIDE COMPOUNDS TO TREAT NEUROPATHIC PAIN
JP2009535386A (ja) 2006-05-03 2009-10-01 アストラゼネカ アクチボラグ チアゾール誘導体および抗腫瘍剤としてのその使用
WO2007136736A2 (en) 2006-05-19 2007-11-29 Codon Devices, Inc. Methods for nucleic acid sorting and synthesis
WO2007135398A1 (en) 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
WO2008060578A2 (en) 2006-11-15 2008-05-22 Cytovia, Inc. 3-aryl-6-aryl-[1,2,4] triazolo[3,4-b][1,3,4] thiadiazoles and related compounds as activators of caspases and inducers of apoptosis and the use thereof
CN101037445A (zh) 2007-04-14 2007-09-19 西北师范大学 一种具有潜在生物活性的咪唑并[2，1－b]－1，3，4－噻二唑衍生物及其合成方法
EP2155753A1 (en) 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US20090156594A1 (en) * 2007-05-21 2009-06-18 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
WO2009019708A2 (en) * 2007-08-09 2009-02-12 Urifer Ltd Pharmaceutical compositions and methods for the treatment of cancer
DK2193133T3 (en) * 2007-09-27 2015-10-05 Fundacion Ct Nac Investigaciones Oncologicas Carlos Iii IMIDAZOLOTHIADIAZOLES USED AS PROTEINKINASE INHIBITORS
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体
EP2307425B1 (en) 2008-07-29 2014-03-26 Merck Patent GmbH Imidazothiadiazoles derivatives

Also Published As

Publication number Publication date
EP2414369A1 (en) 2012-02-08
IL215158A (en) 2015-07-30
MX2011010372A (es) 2012-01-12
NZ595674A (en) 2012-12-21
KR20120034607A (ko) 2012-04-12
CN102388055A (zh) 2012-03-21
BRPI1015367A2 (pt) 2018-02-20
ZA201107350B (en) 2015-06-24
BRPI1015367B8 (pt) 2021-05-25
WO2010112874A1 (en) 2010-10-07
HRP20151126T1 (hr) 2015-11-20
HUE027964T2 (en) 2016-11-28
ES2548571T3 (es) 2015-10-19
HK1166979A1 (zh) 2012-11-16
CY1116880T1 (el) 2017-04-05
DK2414369T3 (en) 2015-09-21
CA2756873C (en) 2018-01-09
CA2756873A1 (en) 2010-10-07
AU2010231162A1 (en) 2011-11-03
CN102388055B (zh) 2015-07-29
PL2414369T3 (pl) 2016-04-29
SI2414369T1 (sl) 2015-12-31
US20120094996A1 (en) 2012-04-19
JP2012522759A (ja) 2012-09-27
IL215158A0 (en) 2011-12-29
KR101727264B1 (ko) 2017-04-14
AU2010231162B2 (en) 2014-12-11
BRPI1015367B1 (pt) 2021-05-11
SG175001A1 (en) 2011-11-28
EA201101435A1 (ru) 2012-04-30
EA022753B1 (ru) 2016-02-29
EP2414369B1 (en) 2015-08-12
PT2414369E (pt) 2015-10-22
US8815918B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
JP2012522759A (ja) イミダゾ［２，１−ｂ］［１，３，４］チアジアゾール誘導体
KR101792837B1 (ko) 키나아제 억제제로서 사용을 위한 이미다조피라진
ES2548768T3 (es) Imidazolotiadiazoles para su uso como inhibidores de proteína quinasa
ES2649144T3 (es) Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
ES2813875T3 (es) Compuestos y procedimientos de uso
US20130131057A1 (en) New bicyclic compounds as pi3-k and mtor inhibitors
JP2014515346A (ja) タンパク質キナーゼ阻害剤としての大環状化合物
US20130065883A1 (en) Triazolo [4, 5- B] Pyridin Derivatives
WO2014151630A2 (en) Compounds and compositions for the treatment of parasitic diseases
US20130029967A1 (en) Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase Inhibitors
JP6564394B2 (ja) 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用
JP2022519764A (ja) 二環式スルホンアミド
WO2023185073A1 (zh) Parp7抑制剂及其用途
WO2022079616A1 (en) Compounds and compositions for the treatment of cryptosporidiosis
HK1166979B (en) Imidazo [2, 1-b] [1, 3, 4] thiadiazole derivatives
HK40083035B (en) Parp7 inhibitor and use thereof
CN118930543A (zh) 三环类化合物及其药物组合物和用途
HK1167142B (en) Imidazopyrazines as inhibitors of protein kinases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130329

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140812

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140910

R150 Certificate of patent or registration of utility model

Ref document number: 5615902

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees